Syngens (Norway) – AI-Powered Synthetic Biology Platform for Strategic Autonomy
38 pages · PDF · 21 August 2025 · Licensed single-user copy, watermarked to the buyer
Tactical Synthetic Biology Artificial Intelligence, Big Data & Analytics Norway
€499 excl. VAT — EU VAT calculated at checkout (VAT ID accepted for reverse charge); invoice issued after payment
One click to Stripe — guest checkout, no account. Your download appears on the confirmation page and arrives by e-mail right after payment (link valid 72 hours, up to 5 downloads).
About this report
In an era when biology and artificial intelligence are emerging as twin pillars of geopolitical competition, Europe is seeking home-grown innovators that can reduce its reliance on foreign technology in critical domains. Synthetic biology – the ability to design and program living systems – is increasingly seen as a strategic frontier.
NATO’s own technologists predict that “the next revolutionary technology cycle will be driven by synthetic biology” , underscoring its promise for healthcare and sustainability alongside its security risks. Syngens is a young Norwegian company operating at this nexus of AI and biotechnology.
Key questions this report answers
- How does Syngens operate at the nexus of AI and synthetic biology to design and program living systems?
- What is the technology readiness of its AI-synthetic-biology platform, and how does it fit NATO's view of synthetic biology as a strategic frontier?
- Which research partners, customers and dual-use markets does the Norwegian firm target?
- What capability gaps, security risks and strategic indicators shape Syngens' role in synthetic biology?
Inside this report
- Executive Summary
- 1. Corporate Identity & Legal Structure
- 2. Strategic Business Profile
- 3. Technology Portfolio Mapping
- 4. Technology Readiness Assessment
- 5. European Strategic Program Participation
- 6. Academic & Research Origins
- 7. Dual-Use Applications & European Market Strategy
- 8. Strategic Partnerships & European Industrial Alliances
- 9. European Market Focus & Operational Domains
- 10. Intellectual Property & European Innovation Assets
- 11. Leadership & European Technical Expertise
- 12. Capability and Gap Analysis
- 13. Strategic Indicators & European Innovation Metrics
Who it's for
Investors screening Syngens, competitors and partners assessing their position, and analysts who need a sourced, structured account of the entity and its technology.
Related reports
Methodology, format & delivery
DFM reports are built from primary and official sources — TED procurement notices, CORDIS and the EU Funding & Tenders Portal, EIB operations, the NATO Innovation Fund portfolio, SIPRI data, official budget documents and company disclosures — read together with the underlying legal texts. Sources are cited in the document; it reflects them as of its publication date (21 August 2025). You receive a 38-page PDF, watermarked to you on every page, delivered on the confirmation page and by e-mail immediately after checkout (personal link valid 72 hours, up to 5 downloads). Guest checkout, single-user licence — Terms of Sale.
Related on DFM
More Tactical reports · Synthetic Biology · Artificial Intelligence, Big Data & Analytics · All reports
Prefer unlimited access?
Prefer unlimited access? Every report like this is included in the DFM Analysis subscription. See plans →